It's been 2 ½ years since Alec Smith died in his Minneapolis apartment as a result of insulin rationing, his mother said Thursday. And it's been 673 days since legislation prompted by his death was first introduced to help people with the drug's soaring cost, according to Minnesota House Speaker Melissa Hortman.
Diabetes advocates, Democratic legislators and Gov. Tim Walz gathered Thursday to present the latest version of a bill they plan to push during the legislative session that starts Feb. 11. The deaths of Minnesotans who could not afford insulin triggered several high-profile calls for action at the State Capitol in recent years. But legislative debates, followed by months of closed-door deal-making over the past year, have failed to produce an aid program.
DFL lawmakers said that they want to pass their bill, which they described as a compromise, early in the session. But proposals exchanged between Democrats and Republicans working behind the scenes paint a picture of entrenched differences.
Over the past couple of weeks, the two sides traded different outlines for an insulin affordability program. From eligibility rules to the process for getting emergency insulin — and most critically, the financial cost to manufacturers — the two sides' proposals remain far apart.
"How many more have to die before something gets done to reduce the skyrocketing price of insulin? How many more people are going to suffer long-term complications from rationing?" said Alec's mother, Nicole Smith-Holt, who has been a leading voice on the issue.
Democrats say they have added elements of GOP proposals into their latest offer. The new DFL plan would add a long-term program for insulin assistance and require aid applicants to show they are legal state residents. Both are GOP ideas.
Republicans have also made compromises, said Sen. Eric Pratt, R-Prior Lake. Their proposal initially focused on longer-term assistance, but they added an emergency element for people to get the drugs they need more quickly.
"To me, it feels like they're more interested in punishing manufacturers than making sure that people have access to affordable insulin," Pratt said.